Cargando…

Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept

BACKGROUND: Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness in older people. Low-grade inflammation is well-known as one of the pathogenic mechanisms in nAMD. Anti-vascular endothelial growth factor (VEGF) therapy is the first-line treatment for nAMD, although mac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Tomohito, Enoki, Toshio, Karasawa, Yoko, Someya, Hideaki, Taguchi, Manzo, Harimoto, Kozo, Takayama, Kei, Kanda, Takayuki, Ito, Masataka, Takeuchi, Masaru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548619/ https://www.ncbi.nlm.nih.gov/pubmed/34721402 http://dx.doi.org/10.3389/fimmu.2021.738521

Ejemplares similares

Comprehensive expression patterns of inflammatory cytokines in aqueous humor of patients with neovascular age-related macular degeneration
por: Sato, Tomohito, et al.
Publicado: (2019)

Intraocular inflammatory cytokines in patients with neovascular age-related macular degeneration before and after initiation of intravitreal injection of anti-VEGF inhibitor
por: Sato, Tomohito, et al.
Publicado: (2018)

Association between aqueous humor and vitreous fluid levels of Th17 cell-related cytokines in patients with proliferative diabetic retinopathy
por: Takeuchi, Masaru, et al.
Publicado: (2017)

Age-related differences in the clinical features of ocular sarcoidosis
por: Takayama, Kei, et al.
Publicado: (2018)

Topical Corticosteroid-Resolved Rubeosis Iridis with Neovascular Glaucoma Caused by Noninfectious Granulomatous Uveitis
por: Sora, Daisuke, et al.
Publicado: (2018)

Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension
por: Yasuda, Mami, et al.
Publicado: (2017)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
por: Ali Said, Yasmin, et al.
Publicado: (2022)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Potential Phototoxicity of Indocyanine Green in Retinal Pigment Epithelial Cells after Angiography under Ambient Illumination
por: Sato, Tomohito, et al.
Publicado: (2018)

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
por: Liberski, Sławomir, et al.
Publicado: (2022)

Reconstitution of disrupted photoreceptor layer in uveitis associated with Behçet’s disease by infliximab treatment
por: Takeuchi, Masaru, et al.
Publicado: (2015)

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
por: Thomas, Michael, et al.
Publicado: (2013)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg, Justus G
Publicado: (2019)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Association between Systemic Factors and Vitreous Fluid Cytokines in Proliferative Diabetic Retinopathy
por: Sato, Tomohito, et al.
Publicado: (2023)

Chronic postcataract endophthalmitis caused by Penicillium species in an immunocompetent patient
por: Kanda, Koji, et al.
Publicado: (2018)

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
por: Blazaki, Styliani, et al.
Publicado: (2023)

Elevated Levels of Cytokines Associated with Th2 and Th17 Cells in Vitreous Fluid of Proliferative Diabetic Retinopathy Patients
por: Takeuchi, Masaru, et al.
Publicado: (2015)

Ziv-aflibercept in macular disease
por: Mansour, Ahmad M, et al.
Publicado: (2015)

HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: You, Qi Sheng, et al.
Publicado: (2018)

Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
por: Yildiz, Dilan, et al.
Publicado: (2021)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Gharbiya, Magda, et al.
Publicado: (2014)

Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
por: Nishikawa, Keiichi, et al.
Publicado: (2019)

Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
por: Itagaki, Kanako, et al.
Publicado: (2020)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease
por: Hsia, Ning-Yi, et al.
Publicado: (2021)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

Efficacy of Aflibercept as initial treatment for neovascular age-related macular degeneration in an Iraqi patient sample
por: Hussein, Zaid Rajab, et al.
Publicado: (2023)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B
Publicado: (2023)

Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment
por: Nagai, Norihiro, et al.
Publicado: (2016)

Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
por: Kato, Nobuhiro, et al.
Publicado: (2023)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
por: Balaratnasingam, Chandrakumar, et al.
Publicado: (2015)

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
por: Parvin, Parmis, et al.
Publicado: (2017)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
por: Elfandi, Sufian, et al.
Publicado: (2021)

Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
por: Pellegrini, Marco, et al.
Publicado: (2020)

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration
por: Kishi, Maya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d1ugsatpvsn08h7dkovemgujtq